634 Matching Annotations
  1. Aug 2021
    1. Craig Spencer MD MPH. (2021, August 6). Even with Delta, the likelihood of severe illness if you’re fully immunized is still a small fraction of the likelihood for the unvaccinated. In other words, nearly every COVID-19-related death right now is preventable with vaccination. [Tweet]. @Craig_A_Spencer. https://twitter.com/Craig_A_Spencer/status/1423674337089949710

    1. Rafael Irizarry. (2021, August 8). Vaccines work in a gif update: COVID19 cases versus vaccination rates in US states through time. The Delta variant effect can be seen clearly starting in July. States with lower vaccination rates are affected much worse. Https://t.co/e0SQpa8Qg0 [Tweet]. @rafalab. https://twitter.com/rafalab/status/1424440520361787392

    1. Justin Baragona on Twitter: “There seems to be a concerted effort today by Fox’s daytime news shows to promote the vaccines to its audience. Dr. Marc Siegel says ‘the Delta variant needs to be a wake-up call to get vaccinated.’ Anchor John Roberts then directs viewers to the government vaccine website. Https://t.co/T5b21nXCfe” / Twitter. (n.d.). Retrieved August 4, 2021, from https://twitter.com/justinbaragona/status/1417178420950220811

    1. John Burn-Murdoch. (2021, May 27). NEW: B.1617.2 is fuelling a third wave in the UK, with not only cases but also hospital admissions rising. Vaccines will make this wave different to those that have come before, but it remains a concern, and one that other countries will soon face. Thread on everything we know: Https://t.co/4825qOqgrl [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1397995388267810818

  2. Jul 2021
    1. Carl T. Bergstrom. (2021, May 27). An update on the B.1.617.2 lineage. I’m concerned. Not because of reduced vaccine efficacy, but simply because a further increase in transmissibility above B.1.1.7 would be quite bad news for countries where vaccination is low and for hopes of near-elimination everywhere. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1398029743954432005

    2. Meaghan Kall 🏳️‍🌈 on Twitter: “The updated cumulative growth curves showing continued exponential growth of B.1.617.2.. Https://t.co/3fmEwU7cP3” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/kallmemeg/status/1397981951907217411

    1. Elisabeth Mahase. (2021, July 26). At least 6 weeks between Pfizer vaccine doses = higher neutralising antibody levels (than a 3-4 wk interval) For those with the delta variant, antibody levels were 2.3-fold higher with the longer interval Preprint from @pitchstudy @bmjlatest https://t.co/E3yOTqNgpa [Tweet]. @emahase. https://twitter.com/emahase_/status/1419604658344112130

    1. Alan McNally 💙. (2021, February 5). Our latest lab data for B.1.1.7 prevalence in Pillar 2 samples, as determined by SGTF. Clearly now plateauing at 80-90%. Which to me suggests there are other lineages as transmissible as B.1.1.7......... Https://t.co/toA0GyVsZz [Tweet]. @alanmcn1. https://twitter.com/alanmcn1/status/1357701944027004929

    1. World Health Organization (WHO). (2021, May 31). Today WHO has announced a new naming system for key #COVID19 variants. The labels are based on the Greek alphabet (i.e. Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. 👉 https://t.co/aYCZfspZyb https://t.co/Gxt14fwVqF [Tweet]. @WHO. https://twitter.com/WHO/status/1399432092333883393

    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., Consortium‡, T. C.-19 G. U. (CoG-U., Volz, E., Faria, N. R., Aanensen, D., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science. https://doi.org/10.1126/science.abj0113

    1. David Fisman. (2021, July 8). Fascinating new preprint on delta vs older variants in well-investigated outbreaks in China. Viral load for delta is 3 log higher, and latent period is shorter too (estimate is 4 days vs 6 days). This may explain much higher R estimates which may be due to elevated viral load [Tweet]. @DFisman. https://twitter.com/DFisman/status/1413126886570536963

    1. Adam Kucharski on Twitter: “Useful data 👇– quick look suggests odds ratio for detection of B.1.617.2 relative to non-B.1.617.2 in vaccinated group compared to controls is 2.7 (95% CI: 0.7-10) after one dose and 1.2 (0.4-3.6) after two...” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/AdamJKucharski/status/1400443351908892675?s=20

  3. Jun 2021
    1. Eric Topol on Twitter: “As the Delta variant (B.1.617.2) becomes dominant throughout the world, there are 2 patterns emerging: —Countries w/ low vaccination rates are seeing both case and fatality rates increase—Countries w/ high vaccination rate: Some case increase and minimal to no fatality increase https://t.co/sSE4RlSeUJ” / Twitter. (n.d.). Retrieved June 28, 2021, from https://twitter.com/EricTopol/status/1408195243279667204

    1. Lewis Spurgin on Twitter: “Perhaps an under appreciated point with the B.1.617.2 variant is that regional PHE teams and local authorities across the country are putting in heroic amounts of effort to break chains of transmission. (1/2)” / Twitter. (n.d.). Retrieved June 27, 2021, from https://twitter.com/LewisSpurgin/status/1395827267297759234

    1. Deepti Gurdasani on Twitter: “I’m still utterly stunned by yesterday’s events—Let me go over this in chronological order & why I’m shocked. - First, in the morning yesterday, we saw a ‘leaked’ report to FT which reported on @PHE_uk data that was not public at the time🧵” / Twitter. (n.d.). Retrieved June 27, 2021, from https://twitter.com/dgurdasani1/status/1396373990986375171

    1. UK is with EU. (2021, January 18). ..The reason we are in this third lockdown is because of the anti lockdowners like Lord Sumption ..We are going in circles, countries who have done well controlled the virus and now have an economic recovery ..And every life matters #GMB @devisridhar speaking truth to power https://t.co/U3BBV0uUSb [Tweet]. @ukiswitheu. https://twitter.com/ukiswitheu/status/1351089812799950850

    1. Bolze, A., Cirulli, E. T., Luo, S., White, S., Cassens, T., Jacobs, S., Nguyen, J., Ramirez, J. M., Sandoval, E., Wang, X., Wong, D., Becker, D., Laurent, M., Lu, J. T., Isaksson, M., Washington, N. L., & Lee, W. (2021). Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States [Preprint]. Infectious Diseases (except HIV/AIDS). https://doi.org/10.1101/2021.06.20.21259195

    1. Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

    1. Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., Hussain, S., Nicod, J., Goldstone, R., Ambrose, K., Hindmarsh, S., Beale, R., Riddell, A., Gamblin, S., Howell, M., … Bauer, D. L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)01290-3

    1. ReconfigBehSci. (2021, May 9). RT @Tuliodna: Confirmed Detection of B.1.617.2 and B.1.1.7 in South Africa by NGS-SA This report was sent to our Health Minister @DrZweliM… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1391416831156514817

  4. May 2021
    1. Prof. Christina Pagel on Twitter: “So Hancock confirms that B.1.617.2 (‘India’ variant) is now dominant in England. Harries says we must remain ‘vigilant’. What does vigilant even mean? That we watch very carefully as a new, more dangerous, variant takes over cos it was so fun last time? Yeah, I’m pissed off” / Twitter. (n.d.). Retrieved May 28, 2021, from https://twitter.com/chrischirp/status/1397951741283405825

    1. Eric Topol. (2021, May 1). Downgrading the concern on B.1.617, the poorly named ‘double mutant’—98% effectiveness of mRNA vaccine in an Israeli outbreak @CT_Bergstrom https://t.co/tGbuwPUmAL —Lab studies: Minimal immune evasion, expected full protection from vaccine @GuptaR_lab https://t.co/AIp24G0ROK https://t.co/AK20UWlDBD [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1388539223230140422

    1. Dr. Tom Frieden. (2021, April 30). Globally, the end of the pandemic isn’t near. More than a million lives depend on improving our response quickly. Don’t be blinded by the light at the end of the tunnel. There isn’t enough vaccine and the virus is gathering strength & speed. Global cooperation is crucial. 1/ [Tweet]. @DrTomFrieden. https://twitter.com/DrTomFrieden/status/1388172436999376899

    1. Eric Topol. (2021, February 17). New reports @NEJM today confirming some immune evasion of the B.1.351 variant (identified in South Africa) to both the mRNA vaccines, in vitro data @BioNTech_Group/@Pfizer and @moderna_tx. Less vaccine efficacy vs B.1.351 has been confirmed in clinical trials for 3 vaccines https://t.co/2N7eKDllso [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1362160675913568256

    1. Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. da S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G., Franco, L. A. M., Ramundo, M. S., Jesus, J. G. de, Andrade, P. S., Coletti, T. M., Ferreira, G. M., Silva, C. A. M., Manuli, E. R., … Sabino, E. C. (2021). Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. https://doi.org/10.1126/science.abh2644

    1. Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., … Group, O. C. V. T. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (SSRN Scholarly Paper ID 3779160). Social Science Research Network. https://doi.org/10.2139/ssrn.3779160

  5. Apr 2021
    1. Eric Topol on Twitter: “The variants of concern/interest fall into a spectrum of immune evasiveness, w/ B.1.351 being most; B.1.1.7, B.1.429 least. This property pertains to potential for reinfection & some reduction in vaccine efficacy My prelim estimates based on publications/preprints, subject to Δ https://t.co/fQZwBCUEGS” / Twitter. (n.d.). Retrieved April 28, 2021, from https://twitter.com/EricTopol/status/1380203664317456385

    1. Trevor Bedford. (2021, January 14). After ~10 months of relative quiescence we’ve started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1349774271095062528

    1. Graham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Modat, M., Drew, D. A., Nguyen, L. H., Polidori, L., Selvachandran, S., Hu, C., Capdevila, J., Koshy, C., Ash, A., Wise, E., … Ourselin, S. (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. The Lancet Public Health, 0(0). https://doi.org/10.1016/S2468-2667(21)00055-4

    1. Lee, L. Y., Rozmanowski, S., Pang, M., Charlett, A., Anderson, C., Hughes, G. J., Barnard, M., Peto, L., Vipond, R., Sienkiewicz, A., Hopkins, S., Bell, J., Crook, D. W., Gent, N., Walker, A. S., Peto, T. E., & Eyre, D. W. (2021). SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. MedRxiv, 2021.03.31.21254687. https://doi.org/10.1101/2021.03.31.21254687

  6. Mar 2021
    1. de Oliveira T, Lutucuta S, Nkengasong J, Morais J, Paixao JP, Neto Z, Afonso P, Miranda J, David K, Ingles L, Amilton P A P R R C, Freitas H R, Mufinda F, Tessema K S , Tegally H, San E J, Wilkinson E, Giandhari J, Pillay S, Giovanetti M, Naidoo Y, Katzourakis A, Ghafari M, Singh L, Tshiabuila D, Martin D, Lessells R. (2021) A Novel Variant of Interest of SARS-CoV-2 with Multiple Spike Mutations Detected through Travel Surveillance in Africa. medRxiv. https://www.krisp.org.za/publications.php?pubid=330. Accessed 26 March 2021.

    1. Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).

      AssayResult: 5.2

      AssayResultAssertion: Normal

      StandardErrorMean: 0.33

    2. A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected

      HGVS: NM_024675.3:c.1732A>G p.(Ser578Gly)

    1. SUPPLEMENTARY DATA

      AssayResult: 97.77

      AssayResultAssertion: Not reported

      PValue: > 0.9999

      Comment: Exact values reported in Table S3.

    2. To this end, 44 missense variants found in breast cancer patients were identified in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar) and/or selected by literature curation based on their frequency of description or amino acid substitution position in the protein (Supplemental Table S1).

      HGVS: NM_024675.3:c.3049G>A p.(Ala1017Thr)

    1. Source Data

      AssayResult: 78.2

      AssayResultAssertion: Not reported

      ReplicateCount: 2

      StandardErrorMean: 7.31

      Comment: Exact values reported in “Source Data” file.

    2. Source Data

      AssayResult: 87.35

      AssayResultAssertion: Not reported

      ReplicateCount: 2

      StandardDeviation: 11.94

      StandardErrorMean: 8.44

      Comment: Exact values reported in “Source Data” file.

    3. We, therefore, analyzed the effect of 48 PALB2 VUS (Fig. 2a, blue) and one synthetic missense variant (p.A1025R) (Fig. 2a, purple)29 on PALB2 function in HR.

      HGVS: NM_024675.3:c.2117C>T p.(T706I)